Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET

Company Participants

Christopher James - VP of Investor Relations

Joseph Ciaffoni - President and CEO

Colleen Tupper - EVP and CFO

Scott Dreyer - Chief Commercial Officer

Conference Call Participants

David Amsellem - Piper Sandler

Serge Belanger - Needham & Co.

Leszek Sulewski - Truist Securities

Oren Livnat - H.C. Wainwright

Operator

Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarter and Full-Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference call is being recorded.

I will now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you. You may begin.

Christopher James

Welcome to Collegium Pharmaceutical's fourth quarter and full-year 2023 earnings conference call. I'm joined today by Joe Ciaffoni, our Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.

Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risk that we may not be able to successfully commercialize our products, that we may incur significant expense and that we may not prevail in current or future litigation pertaining to our business.

These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release on this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at collegiumpharma.com.

I will now turn the call over to our CEO, Joe Ciaffoni.

Joseph Ciaffoni

Thank you, Chris. Good afternoon, and thank you everyone for joining the call. Today, we will discuss our performance during the fourth quarter and full-year 2023 and our focus on operational execution in 2024. As we build a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, we strive to do good as we do well. We are proud of our partnerships with organizations to drive equitable access to STEM education and underserved communities.